Exploring 3 Prominent High Growth Tech Stocks In The United States

Over the last 7 days, the United States market has dropped 2.6%, yet it remains up by 23% over the past year with earnings anticipated to grow by 15% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies with strong innovation potential and robust financial health that can thrive even amidst short-term market fluctuations.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
Super Micro Computer	24.13%	24.28%	★★★★★★
Ardelyx	22.51%	54.38%	★★★★★★
Alkami Technology	21.99%	102.65%	★★★★★★
Clene	61.16%	59.11%	★★★★★★
Alnylam Pharmaceuticals	21.24%	56.34%	★★★★★★
TG Therapeutics	30.06%	45.28%	★★★★★★
Bitdeer Technologies Group	50.20%	126.70%	★★★★★★
Travere Therapeutics	28.68%	62.50%	★★★★★★
Seagen	22.57%	71.80%	★★★★★★
ImmunoGen	26.00%	45.85%	★★★★★★

Click here to see the full list of 233 stocks from our US High Growth Tech and AI Stocks screener.

Let's review some notable picks from our screened stocks.

GoodRx Holdings (NasdaqGS:GDRX)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: GoodRx Holdings, Inc. provides consumers in the United States with tools and information to compare prices and save on prescription drug purchases, with a market cap of approximately $1.74 billion.

Operations: GoodRx Holdings generates revenue primarily from its healthcare software segment, which amounted to $790.39 million. The company enables consumers to save on prescription drug purchases by providing price comparison tools in the United States.

GoodRx Holdings, under the incoming leadership of Wendy Barnes, is poised to leverage her extensive experience in pharmacy benefit management to enhance its strategic positioning within the healthcare sector. With recent initiatives like partnering with Harrow for discounted ophthalmic products and launching an e-commerce platform for direct-to-consumer health product sales, GoodRx is expanding its service offerings beyond traditional prescription savings. These moves, coupled with a robust buyback program repurchasing shares worth $160.11 million, reflect a proactive approach in strengthening market presence and shareholder value. The company's expected revenue growth at 5.9% per year aligns with these expansions but trails the broader US market forecast of 9.2%, indicating a focused yet cautious growth trajectory amidst competitive pressures.

• Click here and access our complete health analysis report to understand the dynamics of GoodRx Holdings.

• Gain insights into GoodRx Holdings' past trends and performance with our Past report.

Halozyme Therapeutics (NasdaqGS:HALO)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Halozyme Therapeutics, Inc. is a biopharma technology platform company that focuses on researching, developing, and commercializing proprietary enzymes and devices globally, with a market cap of approximately $6.11 billion.

Operations: Halozyme focuses on the research, development, and commercialization of proprietary enzymes, generating revenue primarily from these activities amounting to $947.36 million. The company operates in various international markets including the United States, Switzerland, Belgium, and Japan.

Halozyme Therapeutics, showcasing robust growth through strategic product approvals and partnerships, recently celebrated Japan's nod for HYQVIA® and VYVDURA®, leveraging its ENHANZE® technology. These approvals not only underscore Halozyme's innovative edge but also enhance its market presence in Asia. Impressively, the company reported a 34% surge in quarterly revenue to $290.08 million while net income soared by 67% to $137.01 million, reflecting strong operational execution. Additionally, Halozyme's forward-looking R&D investment strategy continues to fuel its pipeline development and expansion into new therapeutic areas, promising sustained growth amidst dynamic healthcare needs.

• Unlock comprehensive insights into our analysis of Halozyme Therapeutics stock in this health report.

• Gain insights into Halozyme Therapeutics' historical performance by reviewing our past performance report.

Precigen (NasdaqGS:PGEN)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company focused on developing gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases, with a market cap of $273.28 million.

Operations: Precigen leverages precision technology to develop gene and cell therapies, focusing on therapeutic areas such as immuno-oncology, autoimmune disorders, and infectious diseases. The company's revenue streams are primarily derived from its Exemplar segment, amounting to $3.89 million.

Precigen's recent strides, including the completion of a biologics license application for PRGN-2012 and securing $79 million through private placements, underscore its commitment to addressing complex medical needs with innovative gene therapies. Despite facing challenges such as a net loss increase to $23.98 million in Q3 2024 and NASDAQ compliance issues, the company is poised for potential growth with PRGN-2012 showing promising clinical outcomes. This scenario reflects Precigen's focus on high-stakes, high-reward biotechnological advancements which may redefine treatment paradigms in niche medical fields.

• Click to explore a detailed breakdown of our findings in Precigen's health report.

• Assess Precigen's past performance with our detailed historical performance reports.

Key Takeaways

• Reveal the 233 hidden gems among our US High Growth Tech and AI Stocks screener with a single click here.
• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com